Muscle News and Research

RSS

RNP granules exit the nucleus via new budding mechanism akin to herpes-type viruses

New evidence published in Cell by Vivian Budnik, PhD, Melissa J. Moore, PhD, and colleagues at the University of Massachusetts Medical School, reveals a novel budding mechanism, similar to the process used by some viruses, capable of exporting large ribonucleoprotein particles from the nucleus to the cytoplasm.

11 May 2012

DYNC1H1 genetic mutation contributes to SMA-LED

Scientists have confirmed that mutations of a gene are responsible for some cases of a rare, inherited disease that causes progressive muscle degeneration and weakness: spinal muscular atrophy with lower extremity predominance, also known as SMA-LED.

11 May 2012

Ixmyelocel-T shows promise against progressive heart failure

An investigational therapy derived from a patient's own bone marrow stem cells improves heart function in some patients with progressive heart failure due to dilated cardiomyopathy (DCM), according to the results of a Phase 2a study presented today as a late-breaking clinical trial at the SCAI 2012 Scientific Sessions.

11 May 2012

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that results from three phase III studies evaluating the use of continuous REVLIMID(lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine.

11 May 2012

ICD therapy significantly reduces mortality in patients with moderate heart failure

St. Jude Medical, Inc., a global medical device company, today announced results of the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) 10-Year Follow-up Study at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions in Boston. The study demonstrated implantable cardioverter defibrillator (ICD) therapy significantly reduces mortality for at least 11 years in patients with moderate heart failure (HF).

11 May 2012

Researchers discover protein that regulates activation of brown fat

Scientists have identified a protein which regulates the activation of brown fat in both the brain and the body's tissues. Their research, which was conducted in mice, was published today, Friday 11 May, in the journal Cell.

11 May 2012

Biosense Webster introduces new curve visualization technology in the U.S.

Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the launch of the new THERMOCOOL SF NAV irrigated ablation catheter with Curve Visualization in the United States.

11 May 2012

Caffeine consumption: How much is too much?

Chocolate, coffee and cola are perhaps three of your favourite consumables; however, they are also three caffeine-rich substances which all contribute to your daily caffeine consumption. According to the BBC, people should not exceed 400mg caffeine a day, and this limit halves for pregnant women, for which only 200mg/day is recommended.

10 May 2012

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA.

10 May 2012

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen Research & Development, LLC announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO, an oral anticoagulant, to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome.

10 May 2012

Morinda Bioactives releases seven new Fit Body Composition Supplements

Morinda Bioactives recently announced the release of seven new Fit Body Composition Supplements, one of which is Fit Joint.

9 May 2012

C3BS’s C-Cath Injection Catheter receives CE Marking

The Belgian biotechnology company, Cardio3--BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces that it has received CE Marking for its intra-myocardial C-Cath Injection Catheter.

9 May 2012

CKD-EPI equation may provide more accurate risk prediction of death, ESRD

Kamyar Kalantar-Zadeh, M.D., M.P.H., Ph.D., principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), is the author of an invited editorial in JAMA. The editorial accompanied a study that included data from more than 1 million adults, and indicated the use of a newer risk prediction equation that classified fewer individuals as having chronic kidney disease and more accurately categorized the risk for death and end-stage renal disease.

9 May 2012

Americans spend only about two hours each week in sports and fitness activities

Americans spend, on average, only about two hours each week participating in sports and fitness activities, according to researchers at Penn State and the University of Maryland who examined U.S. government data from the American Time Use Study.

9 May 2012

Strategies for heart repair to be addressed at UH lecture

With the heart having limited ability to regenerate following injury, heart disease is the primary cause of morbidity and mortality in the developed world. Research impacting strategies for heart repair will be addressed during a lecture May 15 at the University of Houston (UH).

9 May 2012

Researchers discover location and effect of abnormal heart proteins

University of Guelph researchers have found the location and effect of abnormal heart proteins that can cause cardiac failure, a discovery that points to potential new ways to treat the most costly health problem in the world.

9 May 2012

Bioactive formulation for optimal eye health

Morinda Bioactives (formerly Tahitian Noni International) recently announced the release of seven new Fit Body Composition Supplements, one of which is Fit Eye. Fit Eye provides an exclusive formulation of highly effective bioactives derived from the most potent sources, including research-recommended levels of lutein, to support optimal eye health.

8 May 2012

Research grants on facioscapulohumeral dystrophy prove useful as genetic basis is found

Businessman Bill Moss’s determination to fight his untreatable muscle-wasting disease may have paid off. Four years ago, Mr Moss, a former Macquarie Bank Executive Director, established a charitable research foundation, FSHD Global, which partly funded the Italian researchers who made the breakthrough.

8 May 2012

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.

8 May 2012

CardioKinetix Parachute Ventricular Partitioning Device trial data presented at 2012 EuroPCR

CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced that clinical trial data from the first-of-its-kind Parachute Ventricular Partitioning Device for the treatment of patients with ischemic heart failure will be presented at the 2012 EuroPCR Conference in Paris.

7 May 2012